# Evidence Scoring Configuration for MEDIABASE
# This file configures the comprehensive evidence scoring system

# Core scoring parameters
scoring:
  max_evidence_score: 100.0
  confidence_threshold: 0.3
  evidence_decay_days: 1095  # 3 years
  min_evidence_items: 1
  
  # Component score weights for different use cases
  use_case_weights:
    drug_repurposing:
      clinical: 0.40      # Clinical evidence is most important for repurposing
      safety: 0.25        # Safety profile critical for existing drugs
      mechanistic: 0.20   # Mechanism of action understanding
      publication: 0.10   # Literature support
      genomic: 0.05       # Genomic evidence less critical
      
    biomarker_discovery:
      genomic: 0.35       # Genomic evidence most important
      clinical: 0.25      # Clinical validation needed
      publication: 0.20   # Literature support important
      mechanistic: 0.15   # Mechanistic understanding
      safety: 0.05        # Safety less critical for biomarkers
      
    pathway_analysis:
      mechanistic: 0.40   # Mechanistic evidence most important
      publication: 0.25   # Literature support critical
      genomic: 0.20       # Genomic context important
      clinical: 0.10      # Clinical relevance moderate
      safety: 0.05        # Safety less critical for pathways
      
    therapeutic_target:
      clinical: 0.30      # Balanced approach for therapeutic targets
      mechanistic: 0.25   # Mechanism understanding important
      genomic: 0.20       # Genomic evidence important
      publication: 0.15   # Literature support
      safety: 0.10        # Safety considerations

# Source reliability weights (0-1 scale)
source_weights:
  DrugCentral: 0.85
  ChEMBL: 0.90
  Drug_Repurposing_Hub: 0.80
  PharmGKB_Clinical_Annotations: 0.95
  ClinicalTrials.gov: 0.90
  PubMed: 0.75
  FDA_Labels: 0.95
  EMA_Labels: 0.90
  Reactome: 0.85
  GO_Annotations: 0.80

# Clinical phase scoring (0-100 scale)
clinical_phase_scores:
  phase_4: 90          # FDA approved
  phase_3: 75          # Late-stage trials
  phase_2: 60          # Mid-stage trials
  phase_1: 45          # Early-stage trials
  preclinical: 30      # Preclinical studies
  unknown: 20          # No phase information

# Evidence type scoring thresholds
evidence_thresholds:
  clinical_high: 70    # High clinical evidence threshold
  clinical_medium: 40  # Medium clinical evidence threshold
  mechanistic_high: 60 # High mechanistic evidence threshold
  mechanistic_medium: 30 # Medium mechanistic evidence threshold
  publication_high: 50 # High publication support threshold
  publication_medium: 25 # Medium publication support threshold
  genomic_high: 40     # High genomic evidence threshold
  genomic_medium: 20   # Medium genomic evidence threshold
  safety_high: 60      # High safety profile threshold
  safety_medium: 30    # Medium safety profile threshold

# Quality metrics configuration
quality_metrics:
  min_evidence_threshold: 3
  high_confidence_threshold: 0.8
  clinical_relevance_weight: 0.4
  diversity_bonus_factor: 0.1
  consistency_penalty_factor: 0.2

# Cancer research priorities for enhanced scoring
cancer_research_priorities:
  immunotherapy_targets:
    - CD19
    - CD20  
    - CTLA4
    - PD1
    - PDL1
    - TIGIT
    - LAG3
    - TIM3
    
  oncogenes:
    - MYC
    - EGFR
    - HER2
    - KRAS
    - BRAF
    - PI3K
    - AKT
    - MTOR
    - ALK
    - ROS1
    
  tumor_suppressors:
    - TP53
    - RB1
    - BRCA1
    - BRCA2
    - PTEN
    - APC
    - VHL
    - NF1
    
  dna_repair:
    - BRCA1
    - BRCA2
    - ATM
    - CHEK2
    - PALB2
    - RAD51
    - MLH1
    - MSH2
    - MSH6
    - PMS2
    
  cell_cycle:
    - CDK4
    - CDK6
    - CCND1
    - CCNE1
    - RB1
    - E2F1
    - CDK2
    - CDKN1A
    
  apoptosis:
    - BCL2
    - BAX
    - BAK1
    - CASP3
    - CASP9
    - APAF1
    - MCL1
    - BCL2L1
    
  angiogenesis:
    - VEGFA
    - VEGFR1
    - VEGFR2
    - FLT1
    - KDR
    - ANGPT1
    - ANGPT2
    
  metastasis:
    - MMP9
    - MMP2
    - TIMP1
    - CDH1
    - SNAI1
    - TWIST1
    - ZEB1
    - VIM

# Advanced scoring features
advanced_features:
  enable_age_decay: true
  enable_cross_validation: true
  enable_uncertainty_quantification: true
  enable_confidence_intervals: true
  enable_dynamic_weights: false
  
  # Confidence interval calculation
  confidence_interval:
    base_margin_factor: 0.5
    variance_margin_factor: 0.3
    sample_margin_factor: 0.2
    
  # Age decay parameters
  age_decay:
    linear_decay: true
    min_decay_factor: 0.1
    decay_period_days: 1095
    
  # Cross-validation parameters
  cross_validation:
    consistency_threshold: 0.8
    min_sources_for_validation: 2
    variance_penalty_factor: 0.001

# Output and reporting configuration
output:
  score_precision: 2        # Decimal places for scores
  confidence_precision: 3   # Decimal places for confidence values
  include_metadata: true    # Include scoring metadata in output
  include_evidence_items: false  # Include individual evidence items
  
  # Export formats
  export_formats:
    - json
    - csv
    - excel
    
  # Analytics settings
  analytics:
    generate_comparative_analysis: true
    generate_portfolio_recommendations: true
    max_genes_for_comparison: 1000
    top_n_rankings: 20

# Database integration
database:
  batch_size: 100
  commit_frequency: 10
  enable_progress_tracking: true
  enable_parallel_processing: false
  
  # Evidence scoring table settings
  evidence_table:
    enable_partitioning: false
    retention_days: 365
    enable_compression: true
    
  # Analytics refresh settings
  analytics_refresh:
    auto_refresh: true
    refresh_frequency_hours: 24
    refresh_on_scoring_update: true